Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

Published on 8 Dec 2023 on Motley Fool

On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest...

Read the rest of the article

Start tracking your investments with Statfolio

FEATURE For pharmaceutical companies’ stock prices, there are few events as crucial as the result...

Barrons.com 1 Jan 2025

As TipRanks’ Vince Condarcuri stated, NVO stock has slipped significantly due to a string of bad...

TipRanks · via Yahoo Finance 31 Dec 2024

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by...

Insider Monkey · via Yahoo Finance 31 Dec 2024

Despite ever-increasing sales, Eli Lilly stock is down 13% in the fourth quarter, while Novo’s...

Barrons.com 31 Dec 2024

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article...

Insider Monkey · via Yahoo Finance 30 Dec 2024

Loomis Sayles, an investment management company, released its “International Growth Fund” third q...

Insider Monkey · via Yahoo Finance 27 Dec 2024

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in t...

Benzinga 26 Dec 2024

On Dec. 20, the bull thesis for Novo Nordisk stock took a massive hit. In terms of its financial...

Motley Fool · via Yahoo Finance 26 Dec 2024

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In...

Insider Monkey · via Yahoo Finance 25 Dec 2024

Novo Nordisk’s failure favors its arch-rival in the obesity market space, Eli Lilly...treatment. ...

Zacks · via Yahoo Finance 24 Dec 2024